Safety and tolerability
thyroiditis, deaths, Immune-mediated AEs
THYROIDITIS, EVENTS, ADVERSE EVENT
All patients experienced at least one adverse event (AE) of any grade. The summary statistics for AE are shown in Supplementary Table Twenty-seven (61.4%) of the 44 patients required a dose reduction for olaparib owing to an AE (general weakness [Immune-mediated AEs were reported in 36 (81.8%) of the 44 patients. The most frequent immune-related AEs that were causally associated with pembrolizumab were thyroiditis [Overall, there were no newly identified AEs or immune-related AEs, aside from the type and frequency of events that could be expected from each agent based on previous reports. All events were managed conservatively and appropriately. Aside from one patient with MDS, there was no case of discontinuation from the study owing to AEs or treatment-related deaths.